BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country

IntroductionMost pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.MethodsWe retrospec...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Dima Abu Laban, Abeer Alsharif, Maysa Al-Hussaini, Mouness Obeidat, Bayan Maraqa, Qasem Alzoubi, Awni Musharbash, Saad Jaddoua, Raed Ramlawi, Kawther Khaleifeh, Ahmad Kh. Ibrahimi, Nasim Sarhan, Eric Bouffet, Nisreen Amayiri
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Frontiers Media S.A. 2024-09-01
Serie:	Frontiers in Oncology
Ämnen:	BRAF/MEK inhibitors dabrafenib trametinib low-middle-income countries (LMIC) targeted therapy glioma
Länkar:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1417484/full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!